• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[视网膜中央静脉阻塞和分支静脉阻塞。德国、奥地利和瑞士的当前治疗策略]

[Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland].

作者信息

Höh A E, Schaal K B, Dithmar S

机构信息

Schwerpunkt Retinologie, Universitätsaugenklinik Heidelberg, Heidelber, Germany.

出版信息

Ophthalmologe. 2007 Apr;104(4):290-4. doi: 10.1007/s00347-007-1514-0.

DOI:10.1007/s00347-007-1514-0
PMID:17387482
Abstract

BACKGROUND

The main object of this study was to find out what treatment methods are currently preferred for central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) in Germany, Austria and Switzerland.

METHODS

A questionnaire concerning the different medicamentous, surgical and laser treatments available for CRVO and BRVO was developed and sent out to the members of the German Retina Society.

RESULTS

This analysis is based on 124 returned questionnaires. We found that 64% of our colleagues recommend isovolemic hemodilution in patients with CRVO. Pentoxyfyllin infusions are endorsed by 32% and 27%, respectively, for CRVO and BRVO. Panretinal photocoagulation is applied only if neovascularization is present by 39% of those responding, whereas 61% perform prophylactic photocoagulation when there is no visible neovascularization, depending on the degree of ischemia. In the case of macular edema due to BRVO 52% recommend macular grid photocoagulation. Sheathotomy is recommended by 51% for BRVO suggest, and 43% advise radial optic neurotomy (RON) for CRVO. Intravitreal injection of triamcinolone is performed for CRVO or BRVO by 58% and 56%, respectively, and para-bulbar injection of triamcinolone by 2% and 3%. Intravitreal anti-VEGF treatment is applied by 72% of respondents, the majority (94%) using bevacizumab for this purpose.

CONCLUSION

Members of the German Retina Society apply widely differing treatments in patients with CRVO and BRVO. Further clinical studies to evaluate the different therapeutic options seem necessary in order to set up guidelines for the treatment of venous retinal occlusions.

摘要

背景

本研究的主要目的是了解德国、奥地利和瑞士目前针对视网膜中央静脉阻塞(CRVO)和视网膜分支静脉阻塞(BRVO)所偏好的治疗方法。

方法

针对CRVO和BRVO可用的不同药物、手术和激光治疗方法设计了一份问卷,并发送给德国视网膜协会的成员。

结果

本分析基于124份回收的问卷。我们发现,64%的同事推荐对CRVO患者进行等容血液稀释。分别有32%和27%的受访者认可己酮可可碱输注用于CRVO和BRVO。39%的受访者仅在出现新生血管时才进行全视网膜光凝,而61%的受访者在无可见新生血管时根据缺血程度进行预防性光凝。对于BRVO引起 的黄斑水肿,52%的受访者推荐黄斑格栅光凝。51%的受访者建议对BRVO进行鞘膜切开术,43%的受访者建议对CRVO进行放射状视神经切开术(RON)。分别有58%和56%的受访者对CRVO或BRVO进行玻璃体内注射曲安奈德,2%和3%的受访者进行球周注射曲安奈德。72%的受访者采用玻璃体内抗VEGF治疗,大多数(94%)为此使用贝伐单抗。

结论

德国视网膜协会的成员对CRVO和BRVO患者采用广泛不同的治疗方法。为了制定视网膜静脉阻塞的治疗指南,似乎有必要进行进一步的临床研究以评估不同的治疗选择。

相似文献

1
[Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland].[视网膜中央静脉阻塞和分支静脉阻塞。德国、奥地利和瑞士的当前治疗策略]
Ophthalmologe. 2007 Apr;104(4):290-4. doi: 10.1007/s00347-007-1514-0.
2
Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs.法国、德国和意大利视网膜静脉阻塞的治疗:治疗模式、资源消耗及成本分析
Eur J Ophthalmol. 2012 Sep-Oct;22(5):776-84. doi: 10.5301/ejo.5000180.
3
Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study.长期疗效观察:玻璃体内单次注射贝伐单抗联合视网膜全光凝及黄斑格栅样光凝治疗视网膜中央静脉阻塞伴黄斑水肿的疗效:一项初步研究。
Eye (Lond). 2011 Feb;25(2):239-44. doi: 10.1038/eye.2010.225.
4
Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.玻璃体内注射贝伐单抗后再行地塞米松植入与地塞米松植入单药治疗视网膜静脉阻塞伴黄斑水肿的比较。
Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.
5
Results of bevacizumab as the primary treatment for retinal vein occlusions.贝伐单抗作为视网膜静脉阻塞的主要治疗方法的结果。
Br J Ophthalmol. 2010 Aug;94(8):1052-6. doi: 10.1136/bjo.2009.173732.
6
Management of macular edema secondary to central retinal vein occlusion: an evidence-based.治疗视网膜中央静脉阻塞继发黄斑水肿的管理:循证医学。
Adv Ther. 2011 Jan;28(1):40-50. doi: 10.1007/s12325-010-0088-4. Epub 2010 Dec 9.
7
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.SCORE 研究报告 #11:视网膜静脉阻塞眼中新生血管事件的发生率。
Ophthalmology. 2011 Jul;118(7):1364-72. doi: 10.1016/j.ophtha.2010.11.020. Epub 2011 Mar 26.
8
Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study.单剂量玻璃体内注射地塞米松Ozurdex 治疗视网膜静脉阻塞的功能和解剖学结果:6 个月随访——SOLO 研究。
Acta Ophthalmol. 2013 Aug;91(5):e340-7. doi: 10.1111/aos.12020. Epub 2013 May 3.
9
Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update.继发于分支视网膜静脉阻塞的黄斑水肿的管理:基于证据的更新。
Adv Ther. 2011 Jan;28(1):28-39. doi: 10.1007/s12325-010-0089-3. Epub 2010 Dec 9.
10
Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.玻璃体内注射曲安奈德与贝伐单抗治疗视网膜分支静脉阻塞性黄斑水肿后房水细胞因子的变化
Acta Ophthalmol. 2014 May;92(3):e217-24. doi: 10.1111/aos.12219. Epub 2013 Jul 26.

引用本文的文献

1
Predictive Factors for Functional and Anatomical Outcomes After Anti-VEGF Treatment for Macular Edema in Patients with Branch Retinal Vein Occlusion.视网膜分支静脉阻塞患者黄斑水肿抗VEGF治疗后功能和解剖学转归的预测因素
J Ophthalmic Vis Res. 2024 Sep 16;19(3):324-333. doi: 10.18502/jovr.v19i3.13531. eCollection 2024 Jul-Sep.
2
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions.视网膜静脉阻塞性黄斑水肿的低频玻璃体内注射贝伐单抗治疗结果
Clin Ophthalmol. 2017 Jun 21;11:1183-1190. doi: 10.2147/OPTH.S137380. eCollection 2017.
3
Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion.

本文引用的文献

1
[Prophylactic pan-coagulation from ischemic central vein occlusions? Practicability of the results from the Central Vein Occlusion Study Group].
Ophthalmologe. 2003 Dec;100(12):1062-6. doi: 10.1007/s00347-003-0857-4.
2
[Retinal vein occlusions].[视网膜静脉阻塞]
Ophthalmologe. 2003 Jul;100(7):561-77; quiz 578. doi: 10.1007/s00347-003-0820-4.
3
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.缺血性中央静脉阻塞早期全视网膜光凝的随机临床试验。中央静脉阻塞研究组N报告。
抗血管内皮生长因子、激光治疗以及二者联合治疗视网膜中央静脉阻塞的比较
Int J Ophthalmol. 2016 Mar 18;9(3):431-3. doi: 10.18240/ijo.2016.03.18. eCollection 2016.
4
One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.玻璃体内药物递送补充微型泵的一年可行性研究:一项初步研究。
Transl Vis Sci Technol. 2014 Jul 1;3(4):8. doi: 10.1167/tvst.3.3.8. eCollection 2014 May.
5
Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome.贝伐单抗治疗视网膜中央静脉阻塞相关的黄斑囊样水肿:注射时间和频率对最终视力结果的影响。
J Ophthalmol. 2013;2013:974670. doi: 10.1155/2013/974670. Epub 2013 Dec 29.
6
Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.谱域光相干断层扫描 (SD-OCT) 模式及与分支视网膜静脉阻塞相关黄斑水肿对玻璃体内贝伐单抗治疗的反应。
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8. doi: 10.1007/s00417-012-2067-8. Epub 2012 Jun 1.
7
Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.预测因子对视网膜静脉阻塞眼内注射bevacizumab 治疗黄斑水肿变化的影响。
Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):155-9. doi: 10.1007/s00417-009-1167-6. Epub 2009 Sep 9.
8
[Retrospective case analysis of ophthalmological and systemic risk factors in patients with retinal vascular occlusion].视网膜血管阻塞患者眼科及全身危险因素的回顾性病例分析
Ophthalmologe. 2010 May;107(5):446-51. doi: 10.1007/s00347-009-2018-x.
9
Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.光学相干断层扫描(OCT)引导下贝伐单抗治疗视网膜静脉阻塞所致黄斑水肿的长期随访
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41. doi: 10.1007/s00417-009-1151-1. Epub 2009 Jul 26.
Ophthalmology. 1995 Oct;102(10):1434-44.